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Vasodilators and angiotensin-converting enzyme inhibi- 
tors. The prognosis of patients with severe congestive heart 
failure resulting from impaired ventricular systolic function 
is extremely poor. The I year mortality rate of patients with 
severe congestive heart failure who are symptomatic at rest 
or during minimal physical activity and are treated conven- 
tionally is close to 50% (1). Although surgical therapy 
(cardiac transplantation) has the best potential to improve 
prognosis, recently certain vasodilators and angiotensin- 
converting enzyme inhibitors have also been shown to 
improve prognosis in patients with chronic heart failure. In 
the Veterans Administration Heart Failure Trial (V-HEFT) 
(2), the addition of hydralazine and isosorbide dinitrate to 
digitalis and diuretics was associated with a reduction of the 
risk of the 1 year mortality rate by approximately 38%. The 
angiotensin-converting enzyme inhibitors captopril and enal- 
april also have been shown to exert beneficial effects in 
ameliorating symptoms and improving prognosis (1.3). In the 
Cooperative North Scandinavian Enalapril Survival Study 
(CONSENSUS) (I), the addition of enalapril to conventional 
therapy was associated with a reduction in the total mortality 
rate by 40% after 6 months and by 31% after 12 months. 
However, although vasodilators and angiotensin-converting 
enzyme inhibitors improve the prognosis of patients with 
congestive heart failure, a substantial proportion of such 
patients still succumb despite such therapy. 
In the V-HEFT study (2), patients with mild to moderate 
heart failure were randomized and the first and second year 
mortality rate in the hydralazine-isosorbide dinitrate-treated 
group was 12.1% and 25.6%, respectively. In the CONSEN- 
SUS study, in which patients with more severe heart failure 
were enrolled, the 6 month and 1 year mortality rate was 
26% and 36%. respectively, and the total mortality rate in 
this group was still 39%. Thus, any additional therapy with a 
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potential to cause even a modest further improvement in the 
prognosis is likely to be welcome. The pharmacologic agents 
that. in addition to vasodilators and angiotensin-converting 
enzyme inhibitors. might improve the prognosis of patients 
with heart failure, include amiodarone and beta-adrenergic 
blocking agents. 
Ventricular arrhythmias in congestive heart failure. Ami- 
odarone is highly effective in controlling supraventricular 
tachycardias and in suppressing life-threatening ventricular 
arrhythmias. Ventricular arrhythmias occur with a very high 
frequency in patients with chronic congestive heart failure. 
The rate of complex premature ventricular complexes is 
approximately 80% and that of nonsustained ventricular 
tachycardias is about 50% (4). Asymptomatic ventricular 
arrhythmias have been reported in many studies (5-7) to be 
independent predictors of both total mortality and sudden 
death. Holmes et al. (8) observed that the mortality rate after 
14 months was I I% in patients with simple ventricular 
arrhythmias but 50% in those with complex ventricular 
ectopic rhythms: most of these deaths were sudden. In a 
study of 84 patients with heart failure. Dargie et al. (6) found 
frequent ventricular arrhythmias to be the most important 
predictor of total mortality and sudden death. Gradman et al. 
(7) reported that ventricular tachycardia was the best pre- 
dictor of sudden death in 300 patients with mild to moderate 
heart failure who were followed up for 6 to 24 months. 
Although some studies (9) have failed to demonstrate an 
adverse prognostic influence of ventricular arrhythmias, the 
balance of available information supports the supposition 
that the presence of asymptomatic high grade complex 
ventricular arrhythmias is associated with a worse prognosis 
in patients with chronic heart failure. It is not surprising, 
therefore. that antiarrhythmic drugs, particularly amio- 
darone. have been considered by many investigators for 
treatment of such patients. 
The present study: role of amiodarone. Is amiodarone an 
eft‘ective antiarrhythmic agent in patients with chronic heart 
failure‘? In this issue of the Journal, Hamer et al. (lo), in a 
placebo-controlled study, report that significantly fewer pa- 
tients have nonsustained ventricular tachycardia when 
treated with low dose amiodarone. In a similar placebo- 
controlled crossover study, Cleland et al. (11) reported that 
amiodarone reduced the frequency and complexity of ven- 
tricular arrhythmias in patients with chronic heart failure. 
Neri et al. (12) also noted, in a nonrandomized but prospec- 
tive study, that amiodarone produced a substantial (84%) 
reduction in the frequency of ventricular extrasystoles in 
70% to 80% of patients with idiopathic dilated cardiomyop- 
athy during a follow-up period of 3 years. Our own experi- 
ence (unpublished) suggests that amiodarone is highly effec- 
ti1.e in suppressing ventricular arrhythmias in patients with 
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severe chronic heart failure. Although amiodarone appears 
to be an effective antiarrhythmic drug, does it improve the 
prognosis in patients with chronic heart failure’? 
Nicklas et al. (13) reported (in a placebo-controlled study) 
that amiodarone does not reduce mortality or the incidence 
of sudden death in patients with severe cardiomyopathy. In 
their study, however, the sample size (only 50 patients 
randomized) was too small to ascertain the influence of 
amiodarone therapy on mortality. Similarly, in the present 
study by Hamer et al. (lo), the effects of amiodarone therapy 
on prognosis could not be assessed because of the small 
sample size. It is noteworthy, however, that the cardiac 
mortality rate in their patients who received long-term 
amiodarone therapy was only 11% during the long-term 
follow-up in contrast to 40% in the placebo-treated group. 
Furthermore, there was no instance of sudden death in 
patients receiving long-term amiodarone therapy compared 
with four instances in those receiving placebo. In a prospec- 
tive nonrandomized study reported by Neri et al. (12), no 
patient treated with amiodarone died suddenly. Dargie et al. 
(6) reported that patients treated with amiodarone had a 1 
year mortality rate of approximately 10% compared with a 
rate of nearly 40% in patients who were not treated with 
amiodarone. 
tion for enhanced left ventricular ejection fraction, Whatever 
the mechanism, increased left ventricular ejection fraction 
may contribute to the potential improvement in the progno- 
sis of patients receiving amiodarone therapy. As noted in 
other studies (13), Hamer et al. (10) also note a low incidence 
of serious side effects during long-term treatment with low 
dose amiodarone. Thus, low dose amiodarone therapy is 
feasible in the majority of patients and deserves consider- 
ation in appropriate subsets of patients with severe chronic 
congestive heart failure. 
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It is apparent that large scale, randomized controlled 
clinical trials are needed to establish the benefit of amio- 
darone in reducing mortality and sudden death in patients 
with chronic heart failure. Nevertheless, the available infor- 
mation suggests that certain patients are likely to benefit 
from amiodarone therapy. In my view, treatment with ami- 
odarone, along with vasodilators and angiotensin-converting 
enzyme inhibitors, should be given serious consideration in 
patients with severe congestive heart failure in whom malig- 
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